AptarGroup commences clinical study to validate SmartTrack platform

AptarGroup (ATR) announced the commencement of a clinical study to validate its proprietary SmartTrack platform. The platform was developed by Aptar’s drug services company, Nanopharm. If validated, SmartTrack aims to reduce the need for clinical studies in generic drug product approvals by proving it can accurately predict clinical outcomes. The study will involve radio-labelling three different commercially available pressurized metered-dose inhaler drug products and imaging regional lung deposition. These results will be compared with regional deposition predictions from computational fluid dynamic simulations conducted in collaboration with Fluidda, Medimprove and i2c Pharmaceutical Services.